IDUA and Hurler syndrome: Subsequently, we co-transfected the mRNA of this TBE version and sgRNA into GM06214(IDUAW402X) cells derived from a patient with Hurler syndrome, which contain the IDUAW402X mutation (Fig. 5c), achieving an editing efficiency of approximately 25% at the targeted site and significantly restoring the IDUA catalytic activity of the cells (Fig. 5d, e).